JP2020522515A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522515A5
JP2020522515A5 JP2019566695A JP2019566695A JP2020522515A5 JP 2020522515 A5 JP2020522515 A5 JP 2020522515A5 JP 2019566695 A JP2019566695 A JP 2019566695A JP 2019566695 A JP2019566695 A JP 2019566695A JP 2020522515 A5 JP2020522515 A5 JP 2020522515A5
Authority
JP
Japan
Prior art keywords
seq
changed
cdr1
cdr3
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522515A (ja
JP7320457B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/064608 external-priority patent/WO2018220225A1/en
Publication of JP2020522515A publication Critical patent/JP2020522515A/ja
Publication of JP2020522515A5 publication Critical patent/JP2020522515A5/ja
Priority to JP2023119575A priority Critical patent/JP7716448B2/ja
Application granted granted Critical
Publication of JP7320457B2 publication Critical patent/JP7320457B2/ja
Priority to JP2025120997A priority patent/JP2025161816A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566695A 2017-06-02 2018-06-04 アグリカン結合免疫グロブリン Active JP7320457B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023119575A JP7716448B2 (ja) 2017-06-02 2023-07-24 アグリカン結合免疫グロブリン
JP2025120997A JP2025161816A (ja) 2017-06-02 2025-07-18 アグリカン結合免疫グロブリン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762514180P 2017-06-02 2017-06-02
US62/514,180 2017-06-02
PCT/EP2018/064608 WO2018220225A1 (en) 2017-06-02 2018-06-04 Aggrecan binding immunoglobulins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023119575A Division JP7716448B2 (ja) 2017-06-02 2023-07-24 アグリカン結合免疫グロブリン

Publications (3)

Publication Number Publication Date
JP2020522515A JP2020522515A (ja) 2020-07-30
JP2020522515A5 true JP2020522515A5 (https=) 2021-06-17
JP7320457B2 JP7320457B2 (ja) 2023-08-03

Family

ID=62620830

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019566695A Active JP7320457B2 (ja) 2017-06-02 2018-06-04 アグリカン結合免疫グロブリン
JP2023119575A Active JP7716448B2 (ja) 2017-06-02 2023-07-24 アグリカン結合免疫グロブリン
JP2025120997A Pending JP2025161816A (ja) 2017-06-02 2025-07-18 アグリカン結合免疫グロブリン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023119575A Active JP7716448B2 (ja) 2017-06-02 2023-07-24 アグリカン結合免疫グロブリン
JP2025120997A Pending JP2025161816A (ja) 2017-06-02 2025-07-18 アグリカン結合免疫グロブリン

Country Status (15)

Country Link
US (2) US11603401B2 (https=)
EP (1) EP3630818A1 (https=)
JP (3) JP7320457B2 (https=)
KR (2) KR102800125B1 (https=)
CN (2) CN110997716B (https=)
AR (1) AR112069A1 (https=)
AU (2) AU2018277310B2 (https=)
BR (1) BR112019025392A2 (https=)
CA (1) CA3065630A1 (https=)
IL (1) IL270969B2 (https=)
MX (2) MX2019014504A (https=)
NZ (1) NZ759601A (https=)
SG (1) SG10202113337YA (https=)
TW (2) TWI811220B (https=)
WO (1) WO2018220225A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
JP7414736B2 (ja) * 2018-05-30 2024-01-16 中外製薬株式会社 アグリカン結合ドメインおよび運搬部分を含むポリペプチド
GB201918279D0 (en) * 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
US20250002926A1 (en) * 2021-11-12 2025-01-02 Regents Of The University Of Minnesota Compositions and methods for transcriptional activation
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
WO2025133694A1 (en) * 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
ES2155854T3 (es) 1993-06-09 2001-06-01 Unilever Nv Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado.
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
AU7298398A (en) 1996-11-19 1998-06-10 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
KR20010034512A (ko) 1998-02-19 2001-04-25 베렌슨, 론 림프구 활성화 조절을 위한 조성물 및 그 방법
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
CA2370351A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
CN100513570C (zh) 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン.ヴェー. 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
CN101443043A (zh) * 2003-10-08 2009-05-27 杜门蒂斯有限公司 抗体组合物和方法
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
JP2009512844A (ja) * 2005-10-20 2009-03-26 ノルディック・バイオサイエンス・ダイアグノスティクス・アクティーゼルスカブ アグリカンおよびそのフラグメントの検出または定量
GB0521392D0 (en) * 2005-10-20 2005-11-30 Nordic Bioscience As Detection or quantification of aggrecan and its fragments
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
EP2121757A2 (en) 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
HUE035700T2 (en) 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010266272A1 (en) * 2009-07-02 2012-01-19 Glaxo Group Limited Polypeptides and method of treatment
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PT3057992T (pt) * 2013-10-15 2024-07-10 Univ Keio Anticorpo humano contra espécies de adamts do tipo agrecanase para terapêuticas de doenças relacionadas com agrecanase

Similar Documents

Publication Publication Date Title
JP2020522515A5 (https=)
CN111778218B (zh) 噬菌体展示抗体库及基于其淘筛获得的针对新冠病毒SARS-CoV-2的单克隆抗体
JP7203800B2 (ja) ヌクレオチド・ライブラリー
FI3630847T3 (fi) Adamtsia sitovat immunoglobuliinit
JP2015511221A5 (https=)
CA2398155A1 (en) Methods and compositions for linking binding domains in nucleic acid binding proteins
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2017518083A (ja) in vivoでの非共有結合的連結のための方法および組成物
JP2019506839A5 (https=)
WO2001042462A2 (en) Phospholipase a2 inhibitory peptides from python reticulatus
US20110052565A1 (en) Non-aggregating human vh domains
JP2019507341A5 (https=)
RU2020113713A (ru) Слитый белок, содержащий молекулу fgf-18
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
JP2024023268A5 (https=)
AU5623801A (en) 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides
ATE446510T1 (de) Kontrolle des wachstums und der reparatur von gastrointestinalgewebe durch gastrokine
JP2025512512A5 (https=)
McCarthy et al. Altering the fine specificity of an anti-Legionella single chain antibody by a single amino acid insertion
RU2019143684A (ru) Полипептиды, связывающиеся с adamts5, mmp13 и аггреканом
JP6894926B2 (ja) 改変されたトランスフェリンのdna結合ドメイン、組み換えdnaポリメラーゼ及び調製方法
RU2019143589A (ru) Иммуноглобулины, связывающие аггрекан
WO2003031590A3 (en) Nucleic acids encoding linked chromo/fluorescent domains and methods for using the same
JP2006506994A5 (https=)
BR0003768A (pt) Oligocorpos monoclonais e policlonais (reagentes sintéticos semelhantes a anticorpos baseados em oligonucleotìdeos) e um método de produção dos oligocorpos